Close Menu

This article has been updated from a previous version to include comments from Trovagene's Q3 earnings call.

NEW YORK (GenomeWeb) – Trovagene reported after the close of the market on Monday flat year-over-year third quarter revenues as it trimmed its net loss in half.

For the three months ended Sept. 30, 2015, the San Diego-based molecular diagnostics developer reported $57,000 in revenues. The company reported $51,000 in royalty revenue compared to $57,000 a year ago, and $6,000 in diagnostic service revenue compared to none in Q3 2014.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.